<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877485</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-36535</org_study_id>
    <nct_id>NCT02877485</nct_id>
  </id_info>
  <brief_title>The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation</brief_title>
  <official_title>The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine if intranasal corticosteroids have an effect on&#xD;
      nasal obstruction in patients with nasal septal deviation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were identified at their initial visit to the Stanford Facial Plastic and&#xD;
      Reconstructive Surgery Clinic, an academic referral center, in consultation for nasal&#xD;
      obstruction. If eligible and interested in participating, patients provided written informed&#xD;
      consent prior to randomization.&#xD;
&#xD;
      Eligible participants were patients over the age of 18 years of age with the presence of&#xD;
      nasal septal deviation as identified by physical examination, as well as a baseline NOSE&#xD;
      score of 35 or greater. Exclusion criteria included a history of nasal or septal surgery, use&#xD;
      of intranasal steroids in the three months preceding enrollment, use of systemic steroids in&#xD;
      the six months preceding enrollment, and pregnancy or active breastfeeding at the time of&#xD;
      enrollment. In order to maximize generalizability of the study, no medications other than&#xD;
      systemic and intranasal steroids were used as exclusion criteria.&#xD;
&#xD;
      All study participants received 6 weeks of therapy with an intranasal steroid spray, Nasacort&#xD;
      (Chattem Inc), which consists of the steroid triamcinolone acetonide, as well as 6 weeks of&#xD;
      placebo with Ayr saline spray (B.F. Ascher). These two study drugs were packaged identically&#xD;
      by a local pharmacist and labelled Drug A and Drug B. Nasacort was selected as the intranasal&#xD;
      steroid following pharmacist consultation, as this intranasal steroid is less scented than&#xD;
      others and therefore was less likely to be distinguishable from the placebo to participants.&#xD;
      Participants were instructed to use both drugs as follows: 1 spray per nostril twice a day.&#xD;
      Researchers, statistical analysts, and study participants were blinded to the identity of the&#xD;
      two drugs until the conclusion of the study. A duration of 6 weeks per drug was selected&#xD;
      based on the most commonly observed insurance requirements seen in our practice. Following&#xD;
      unblinding, it was determined that Drug A was the placebo, the saline spray, and Drug B was&#xD;
      the test drug, the nasal steroid.&#xD;
&#xD;
      Following completion of both study drugs, patients were offered surgical intervention. If&#xD;
      interested and medically cleared for surgery, patients underwent surgery. All surgeries were&#xD;
      performed by the senior author and included open septorhinoplasty to address septal&#xD;
      deviation, with repair of nasal valve stenosis and inferior turbinate reduction performed in&#xD;
      some patients as deemed necessary by the senior author.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">August 15, 2019</completion_date>
  <primary_completion_date type="Actual">August 15, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray)</measure>
    <time_frame>Pre-spray NOSE score - 6 weeks Post spray NOSE score- 2 weeks washout - Pre spray Pre-spray NOSE score - 6 weeks Post spray NOSE score</time_frame>
    <description>Nasal Obstruction Symptom Evaluation (NOSE) scale:&#xD;
A quality of life (QOL) instrument developed to assess nasal obstruction symptoms in patients undergoing septoplasty. It consists of a 5-item questionnaire, scored on a 5-point (0-4) Likert scale. The raw score ranges from 0-20, which is scaled to a score of 0-100 by multiplying the raw score by 5, where '0' represents 'no problem' and, and '100' represent 'worst problem.'</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery.</measure>
    <time_frame>Postoperative time interval (months): 1-2 , 3-5 , 6-9, 9-12, &gt;12.</time_frame>
    <description>Nasal Obstruction Symptom Evaluation (NOSE) scale:&#xD;
A quality of life (QOL) instrument developed to assess nasal obstruction symptoms in patients undergoing septoplasty. It consists of a 5-item questionnaire, scored on a 5-point (0-4) Likert scale. The raw score ranges from 0-20, which is scaled to a score of 0-100 by multiplying the raw score by 5, where '0' represents 'no problem' and, and '100' represent 'worst problem.'</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Nasal Obstruction</condition>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide then Ayr spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ayr spray then triamcinolone acetonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>2 sprays sprayed to both nostrils daily for 42 days.</description>
    <arm_group_label>Ayr spray then triamcinolone acetonide</arm_group_label>
    <arm_group_label>Triamcinolone acetonide then Ayr spray</arm_group_label>
    <other_name>Nasacort</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ayr saline nasal mist</intervention_name>
    <description>110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
    <arm_group_label>Ayr spray then triamcinolone acetonide</arm_group_label>
    <arm_group_label>Triamcinolone acetonide then Ayr spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than 18&#xD;
&#xD;
          -  NOSE score greater than 55&#xD;
&#xD;
          -  Nasal septal deviation on exam&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intranasal steroid use within the last three months&#xD;
&#xD;
          -  Current systemic steroid use&#xD;
&#xD;
          -  Prior septal surgery&#xD;
&#xD;
          -  Individuals who are pregnant or actively breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam P Most, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sedaghat AR, Busaba NY, Cunningham MJ, Kieff DA. Clinical assessment is an accurate predictor of which patients will need septoplasty. Laryngoscope. 2013 Jan;123(1):48-52. doi: 10.1002/lary.23683. Epub 2012 Nov 20.</citation>
    <PMID>23169536</PMID>
  </reference>
  <reference>
    <citation>Stewart MG, Witsell DL, Smith TL, Weaver EM, Yueh B, Hannley MT. Development and validation of the Nasal Obstruction Symptom Evaluation (NOSE) scale. Otolaryngol Head Neck Surg. 2004 Feb;130(2):157-63.</citation>
    <PMID>14990910</PMID>
  </reference>
  <reference>
    <citation>Lipan MJ, Most SP. Development of a severity classification system for subjective nasal obstruction. JAMA Facial Plast Surg. 2013 Sep-Oct;15(5):358-61. doi: 10.1001/jamafacial.2013.344.</citation>
    <PMID>23846399</PMID>
  </reference>
  <reference>
    <citation>Teti VP, Akdagli S, Most SP. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction. JAMA Facial Plast Surg. 2016 May 1;18(3):165-70. doi: 10.1001/jamafacial.2015.2039.</citation>
    <PMID>26747790</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2016</study_first_submitted>
  <study_first_submitted_qc>August 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <results_first_submitted>May 2, 2020</results_first_submitted>
  <results_first_submitted_qc>August 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 13, 2020</results_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sam P. Most</investigator_full_name>
    <investigator_title>Chief, Division of Facial Plastic and Reconstructive Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasal Obstruction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 24, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02877485/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT02877485/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Triamcinolone Acetonide Then Ayr Spray</title>
          <description>This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.&#xD;
Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.&#xD;
Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
        </group>
        <group group_id="P2">
          <title>Ayr Spray Then Triamcinolone Acetonide</title>
          <description>This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.&#xD;
Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.&#xD;
Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Triamcinolone Acetonide Then Ayr Spray</title>
          <description>This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.&#xD;
Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.&#xD;
Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
        </group>
        <group group_id="B2">
          <title>Ayr Spray Then Triamcinolone Acetonide</title>
          <description>This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.&#xD;
Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.&#xD;
Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="42"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="10.1"/>
                    <measurement group_id="B2" value="33.7" spread="14.4"/>
                    <measurement group_id="B3" value="33.0" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="20"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray)</title>
        <description>Nasal Obstruction Symptom Evaluation (NOSE) scale:&#xD;
A quality of life (QOL) instrument developed to assess nasal obstruction symptoms in patients undergoing septoplasty. It consists of a 5-item questionnaire, scored on a 5-point (0-4) Likert scale. The raw score ranges from 0-20, which is scaled to a score of 0-100 by multiplying the raw score by 5, where '0' represents 'no problem' and, and '100' represent 'worst problem.'</description>
        <time_frame>Pre-spray NOSE score - 6 weeks Post spray NOSE score- 2 weeks washout - Pre spray Pre-spray NOSE score - 6 weeks Post spray NOSE score</time_frame>
        <population>Patients requiring nasal surgery for nasal breathing complaints, nasal cosmesis or both.</population>
        <group_list>
          <group group_id="O1">
            <title>Triamcinolone Acetonide Then Ayr Spray</title>
            <description>This study arm will start with 6 weeks of therapy with the intranasal steroid, followed by 6 weeks of therapy with a placebo, with a two week washout period in between treatments.&#xD;
Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.&#xD;
Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
          </group>
          <group group_id="O2">
            <title>Ayr Spray Then Triamcinolone Acetonide</title>
            <description>This study arm will start with 6 weeks of placebo, followed by 6 weeks of therapy with the intranasal steroid, with a two week washout period in between treatments.&#xD;
Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.&#xD;
Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Obstruction as Measured by Nasal Obstruction Symptom Evaluation (NOSE) Scores Following Therapy With Treatment (Triamcinolone Acetonide) and Placebo (Ayr Saline Spray)</title>
          <description>Nasal Obstruction Symptom Evaluation (NOSE) scale:&#xD;
A quality of life (QOL) instrument developed to assess nasal obstruction symptoms in patients undergoing septoplasty. It consists of a 5-item questionnaire, scored on a 5-point (0-4) Likert scale. The raw score ranges from 0-20, which is scaled to a score of 0-100 by multiplying the raw score by 5, where '0' represents 'no problem' and, and '100' represent 'worst problem.'</description>
          <population>Patients requiring nasal surgery for nasal breathing complaints, nasal cosmesis or both.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Pre - spray 1 NOSE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="20.4"/>
                    <measurement group_id="O2" value="68.5" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post - spray 1 / pre- spray 2 NOSE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" spread="20.7"/>
                    <measurement group_id="O2" value="65.8" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post - spray 2 NOSE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="20.6"/>
                    <measurement group_id="O2" value="61.5" spread="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>1) H0: mean change in NOSE score from baseline after in study group 1 = mean change in NOSE score from baseline in study group 2&#xD;
Power calculation: To detect a 20% difference in NOSE scores with 80% power and a 2-sided alpha level of 0.05 required 20 participants per study group, for a total of 40 participants.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <p_value_desc>Statistical Tests:&#xD;
Independent t-test to assess differences in mean change in NOSE scores when comparing the two study groups, and p&lt;0.05 deemed statistically significant</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.0</ci_lower_limit>
            <ci_upper_limit>8.9</ci_upper_limit>
            <estimate_desc>Change in Mean NOSE score from baseline to post saline versus change in NOSE score from baseline to post intranasal steroid.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery.</title>
        <description>Nasal Obstruction Symptom Evaluation (NOSE) scale:&#xD;
A quality of life (QOL) instrument developed to assess nasal obstruction symptoms in patients undergoing septoplasty. It consists of a 5-item questionnaire, scored on a 5-point (0-4) Likert scale. The raw score ranges from 0-20, which is scaled to a score of 0-100 by multiplying the raw score by 5, where '0' represents 'no problem' and, and '100' represent 'worst problem.'</description>
        <time_frame>Postoperative time interval (months): 1-2 , 3-5 , 6-9, 9-12, &gt;12.</time_frame>
        <population>Pooled analysis of 35 participants who underwent surgery. Paired t-tests were used to assess differences in mean change in NOSE scores at five post-operative time points compared to baseline NOSE scores.</population>
        <group_list>
          <group group_id="O1">
            <title>Surgery Patients</title>
            <description>Participants who underwent surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Obstruction Symptom Evaluation (NOSE) Score Following Surgery in Subset of Patients Who Elect to Undergo Surgery.</title>
          <description>Nasal Obstruction Symptom Evaluation (NOSE) scale:&#xD;
A quality of life (QOL) instrument developed to assess nasal obstruction symptoms in patients undergoing septoplasty. It consists of a 5-item questionnaire, scored on a 5-point (0-4) Likert scale. The raw score ranges from 0-20, which is scaled to a score of 0-100 by multiplying the raw score by 5, where '0' represents 'no problem' and, and '100' represent 'worst problem.'</description>
          <population>Pooled analysis of 35 participants who underwent surgery. Paired t-tests were used to assess differences in mean change in NOSE scores at five post-operative time points compared to baseline NOSE scores.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline NOSE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative period: 1-2 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative period:3-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative period:6-9 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative period: 9-12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postoperative period: &gt;12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>H0: Mean pre- treatment baseline patient NOSE score = Mean post- treatment baseline patient NOSE score.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Paired t-tests to assess differences in mean NOSE score when the treatment groups were combined (saline arm+ steroid arm) at five post-operative time intervals compared to the combined preoperative baseline scores. Significance at p&lt;0.05.</p_value_desc>
            <method>Paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-50</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>27.6</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks after start of treatment (after drug spray 1). 14 weeks after start of treatment (after drug spray 2)</time_frame>
      <desc>No adverse events to report</desc>
      <group_list>
        <group group_id="E1">
          <title>Triamcinolone Acetonide</title>
          <description>Triamcinolone Acetonide: 2 sprays sprayed to both nostrils daily for 42 days.</description>
        </group>
        <group group_id="E2">
          <title>Ayr Spray</title>
          <description>Ayr saline nasal mist: 110mcg (2 sprays) sprayed to both nostrils daily for 42 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The presence and degree of inferior turbinate hypertrophy, the presence of allergic rhinitis, chronic sinusitis, and other forms of nasal mucosal edema, were not assessed or included in analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sam P. Most MD</name_or_title>
      <organization>Stanford Facial Plastic and Reconstructive Surgery</organization>
      <phone>650-736-3223</phone>
      <email>smost@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

